Capital International Investors’s Autolus Therapeutics AUTL Stock Holding History

Capital International Investors’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,272,728	Closed	-$13M	–	451
2021 Q1	$13M	Buy	2,272,728 +1,050,040	+86%	+$7.77M	﹤0.01%	408
2020 Q4	$10.9M	Hold	1,222,688	–	–	﹤0.01%	405
2020 Q3	$14.2M	Hold	1,222,688	–	–	﹤0.01%	382
2020 Q2	$19.6M	Hold	1,222,688	–	–	0.01%	351
2020 Q1	$7.32M	Buy	1,222,688 +547,800	+81%	+$5.06M	﹤0.01%	357
2019 Q4	$8.91M	Hold	674,888	–	–	﹤0.01%	358
2019 Q3	$8.38M	Buy	674,888 +186,000	+38%	+$2.46M	﹤0.01%	362
2019 Q2	$7.87M	Hold	488,888	–	–	﹤0.01%	366
2019 Q1	$15.4M	Hold	488,888	–	–	0.01%	338
2018 Q4	$16.1M	Hold	488,888	–	–	0.01%	320
2018 Q3	$14.7M	Buy	+488,888	New	+$13.2M	0.01%	335

Other funds holding AUTL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital International Investors's AUTL Position: Q2 2021 in Review

Capital International Investors sold out of Autolus Therapeutics (AUTL) in Q2 2021, closing a stake of 2,272,728 shares — an estimated $13M sold.

Capital International Investors first reported a position in AUTL in Q3 2018 and held it in 11 quarters. The position peaked at $19.6M in Q2 2020. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2021.

Capital International Investors reported no remaining Autolus Therapeutics position as of Q2 2021 after selling out during the quarter.
Capital International Investors sold 2,272,728 Autolus Therapeutics shares in Q2 2021, an estimated $13M.
Capital International Investors first reported a position in Autolus Therapeutics in Q3 2018 and held it in 11 quarters.
Capital International Investors's Autolus Therapeutics position peaked at $19.6M in Q2 2020.
69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2021.

Based on Capital International Investors's 13F filing for Q2 2021, filed 16 Aug 2021.